Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 13, No. 8, 2014, pp. 1353-1359
Bioline Code: pr14186
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 13, No. 8, 2014, pp. 1353-1359
© Copyright 2014 - Tropical Journal of Pharmaceutical Research
Preliminary Investigation of Risk Factors Causing Dyskinesias in Parkinson’s Disease in South Africa|
Gaida, Razia & Truter, Ilse
Purpose: To determine the risk factors involved in the onset of dyskinesias in patients suffering from
Parkinson’s disease in South Africa.
Methods: A questionnaire survey and medical record review were conducted. A total of 43 patients
with Parkinson’s disease in two metropolitan areas were included in the study.
Results: The number of patients with dyskinesias indicated by medical records (n =10) was less than
the number of patients with self-reported dyskinesias (n = 13). According to the patient interviews, the
mean prescribed daily dose (PDD) of levodopa was 750 ± 452 mg. Twelve patients had been using
levodopa for > 10 years. Mean PDD of levodopa according to the medical records was 809 ± 514 mg,
with dyskinetic patients receiving a higher average PDD of 870 ± 590 mg. Half of the patients with
dyskinesias were diagnosed more than 10 years ago. Patients with dyskinesias were diagnosed with
Parkinson’s disease at a younger age (11.63 % dyskinetic patients were diagnosed between 40 and 60
years), and experienced longer disease duration. There were no gender differences (p = 0.80) in the
incidence of dyskinesias.
Conclusion: Higher doses of levodopa, longer disease duration and a longer duration of levodopa
therapy were risk factors for dyskinesias. Further studies are needed on the incidence of dyskinesias.
Parkinson’s disease; Dyskinesias; Levodopa; Drug utilisation South Africa
Alternative site location: http://www.tjpr.org